Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole in Glioblastoma
NCT04825275Phase 1Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- May 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of posaconazole in glioblastoma (GBM) (2 arms), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Posaconazole Concentration in Cerebrospinal Fluid Using Microdialysis Catheters. Started May 2022; status: terminated.
02
Drugs
posaconazole
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04825275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825275.